Motivia builds a platform that combines behavioral science principles with AI-driven personalization to improve patient adherence to chronic therapies. It operates under a B2B2C model, integrating with pharmaceutical laboratories and health insurers who then offer the service to patients as part of adherence programs. The company is strategically focused on GLP-1 treatments for obesity and type 2 diabetes, where discontinuation rates are high and improving adherence creates value for both labs and payers. Motivia positions its solution to address psychological and logistical barriers to sustained treatment rather than only sending reminders. The startup is early-stage following a US$1.2M pre-seed raise and aims to use capital to validate and scale its model through pilots and partnerships with insurers and pharmaceutical clients.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Jun 2026